Cardiovascular disease
Conditions
Interventions
EPA fish oil group:Participants consumed 3 grams of high-purity EPA fish oil per day for four weeks of the intervention, while consuming other EPA-rich foods (e.g., deep-sea fish, etc.) no more than t
Corn oil group:Participants will receive 3 grams of corn oil per day for four weeks of the intervention, while consuming other EPA-rich foods (e.g., deep-sea fish, etc.) no more than two times per wee
High temperature ozone chamber exposure group:All 48 participants will expose to a combination of 32°C, 200 ppb ozone for 2 hours.
Sponsors
Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Adults between the ages of 18-50; 2. In good health, no medically diagnosed cardiopulmonary metabolic diseases and their risk factors, such as hypertension, hyperglycemia, hyperlipidemia, obesity, asthma, COPD, etc.; 3. Male: Female = 1:1.
Exclusion criteria
Exclusion criteria: 1. Those who eat EPA-rich fish (such as salmon and mackerel) >=2 times a week; 2. Smokers or those who have quit smoking for less than 3 years; 3. Those who are trying to get pregnant, pregnant or breastfeeding; 4. Those who have had major surgery in the past 5 years; 5. BMI>=37.5 or BMI<18.5; 6. Those who are unable to collect blood; 7. Those who are unable to sign the informed consent form; 8. Recent (past 1 month) use of omega-3 fatty acid supplements, antioxidants (such as vitamin C, vitamin E, ß-carotene, selenium, etc.), ß-receptor blockers or anti-inflammatory drugs; 9. Those who are allergic to EPA; 10. Those who are allergic to pollen; 11. Participated in other clinical trials in the past 3 months; 12. There are objective circumstances that are inconvenient to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ß-Thromboglobulin;Soluble P-selectin;Platelet aggregation;Monocyte-platelet aggregates;Platelet fibrinogen binding;Thromboxane B2;Platelet activating factor;Thrombin-antithrombin complex;Prothrombin fragment 1+2;Factor VIIa;Factor VIIc;Factor VIIIc;Thrombin time;Prothrombin time;Activated partial prothromboin time;Fibrinogen;Antithrombin;Endogenous thrombin potential;Fibrin monomers;Thrombotic Precursor Protein;Protein C and Protein S;Plasmin;Plasminogen;a2-Antiplasmin;Tissue plasminogen activator;Urine plasminogen activator;Plasminogen activator inhibitor type-1;Plasmin-antiplasmin complexes;D-dimer;Fibrinogen Degradation Products;vascular endothelial growth factor;Soluble E-selectin;von Willebrand factor;Soluble thrombomodulin;Endothelin;Intercellular adhesion molecule-1 ;Blood Flow Velocity;Pulse Wave Velocity; | — |
Secondary
| Measure | Time frame |
|---|---|
| White Blood Cell;Monocyte;Neutrophil ;Eosinophil;C-Reactive Protein;Arachidonic Acid;Malondialdehyde;Total Cholesterol;Triglycerides;Low-Density Lipoprotein Cholesterol;High-Density Lipoprotein Cholesterol;Apolipoprotein A1;Apolipoprotein B;Lipoprotein(a);Systolic Blood Pressure;Diastolic Blood Pressure;Oxygen Saturation;Fractional Exhaled Nitric Oxide; | — |
Countries
China
Contacts
Public ContactTeng Wang
Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed